Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 134

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 134
---
 period,
our Depositary Shares may be subject to delisting by NASDAQ. This could inhibit the ability of our holders of Depositary Shares to trade
their shares in the open market, thereby severely limiting the liquidity of such shares, and the price of our Depositary Shares could
decline. Delisting may further impair our ability to raise capital.

In
our opinion, the environment for financing of small and micro-cap biotech companies continues to be challenging. While this may present
acquisition and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings
by us are likely to be dilutive. We continue to evaluate financing options, including those connected to acquisitions and/or mergers,
potentially available to the Company. Any alternatives considered are contingent upon the agreement of counterparties and accordingly,
there can be no assurance that any of alternative courses of action to finance the Company would be successful. This requirement for additional
financing in the short term represents a material uncertainty that may cast significant doubt upon our ability to continue as a going
concern. Should it become evident in the future that there are no realistic financing options available to us which are actionable before
its cash resources run out then we will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial
statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be
stated at net realizable value and all liabilities would be accelerated to current liabilities.

As
noted herein, we believe there are adequate options and time available to secure additional financing for us and after considering the
uncertainties, we consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements.

Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement
and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical
trials. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner
than we currently expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities,
our business, financial condition and results of operations could be materially adversely affected.

Cash Flows

The following table presents a summary
of the primary sources and uses of cash from continuing activities for the six months ended